Trial Profile
Very Rapid and Rapid Virological Response as Predictors of Response to Sofosbuvir / Daclatasvir Treatment of HCV Related Liver Disease
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jul 2018 Planned initiation date changed from 1 Apr 2018 to 1 Aug 2018.
- 04 Apr 2018 New trial record